Histone Deacetylase Inhibitors Demonstrate Significant Preclinical Activity as Single Agents, and in Combination with Bortezomib in Waldenstr?m's Macroglobulinemia

详细信息    查看全文

• 作者：Jenny Y. Sun ; Lian Xu ; Hsuyi Tseng ; Bryan Ciccarelli ; Mariateresa Fulciniti ; Zachary R. Hunter ; Kaveh Maghsoudi ; Evdoxia Hatjiharissi ; Yangsheng Zhou ; Guang Yang ; Biao Zhu ; Xia Liu ; P Gong ; Leukothea Ioakimidis ; Patricia Sheehy ; Christopher J. Patterson ; Nikhil C. Munshi ; Owen A. O'Connor ; Steven P. Treon ; ^{steven_treon@dfci.harvard.edu}
• 刊名：Clinical Lymphoma Myeloma and Leukemia
• 出版年：2011
• 出版时间：February 2011
• 年：2011
• 卷：11
• 期：1
• 页码：152-156
• 全文大小：1025 K

文摘

We studied the role of histone deacetylase inhibitors in Waldenstrom's macroglobulinemia (WM). Gene expression profiling of bone marrow CD19+ cells from 30 patients and 10 healthy donors showed overexpression of HDAC4, HDAC9, and Sirt5, with validation of HDAC9 overexpression by q-PCR in primary and BCWM.1 cells. Suberoylanilide hydroxamic acid, trichostatin A, panobinostat, and sirtinol demonstrated dose-dependent killing of BCWM.1 cells. TSA showed the greatest potency with IC50 of 70 nM. Importantly, HDAC9 activity was decreased following TSA treatment suggesting an essential role for this HDAC in WM therapy. The combination of bortezomib plus HDAC inhibitors resulted in at least additive tumor cell killing in BCWM.1 cells. TSA and bortezomib-induced apoptosis depended on a similar set of caspase activation, whereas their effect on cell cycle regulators was distinctly different. These results provided a framework for examining HDAC inhibitors as monotherapy, as well as combination therapy with bortezomib in WM.